Injae Shin

Injae Shin

Auto-generated profile, based on publicly available information

Injae Shin

KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HCHanna Cho
Hanna Cho
ISInjae Shin
Injae Shin
HYHojong Yoon
Hojong Yoon
EJEunhye Jeon
Eunhye Jeon
JLJiwon Lee
Jiwon Lee
TSTaebo Sim
Taebo Sim

Verified
Journal Article
Open access
PDF file
NKNamkyoung Kim
Namkyoung Kim
ISInjae Shin
Injae Shin
JLJiwon Lee
Jiwon Lee
JEJEON Eunhye
JEON Eunhye
Younghoon KimYounghoon Kim
Younghoon Kim
TSTaebo Sim
Taebo Sim
Melanoma accounts for the majority of skin cancer deaths. About 50% of all melanomas are associated with BRAF mutations. BRAF mutations are classified into three classes with regard to dependency on RAF dimerization and RAS signaling. The most frequently occurring class I BRAF V600 mutations are sensitive to vemurafenib whereas class II and class III mutants, non-V600 BRAF mutants are resistant to vemurafenib. Herein we report six pyrimido[4,5-d]pyrimidin-2-one derivatives possessing highly potent anti-proliferative activities on melanoma cells harboring BRAF class I/II/III mutants. Novel and most potent derivative, SIJ1777, possesses not only two-digit nanomolar potency but also 2 to 14-fold enhanced anti-proliferative activities compared with reference compound, GNF-7 against melanoma cells (SK-MEL-2, SK-MEL-28, A375, WM3670, WM3629). Moreover, SIJ1777 substantially inhibits the activation of MEK, ERK, and AKT and remarkably induces apoptosis and significantly blocks migration, invasion, and anchorage-independent growth of melanoma cells harboring BRAF class I/II/II mutations while both vemurafenib and PLX8394 have little to no effects on melanoma cells expressing BRAF class II/III mutations. Taken together, our six GNF-7 derivatives exhibit highly potent activities against melanoma cells harboring class I/II/III BRAF mutations compared with vemurafenib as well as PLX8394.

1 November 2015
Verified
Conference Paper
Closed access
ISIn-Jae Shin
In-Jae Shin
DEDoo-Seop Eom
Doo-Seop Eom
BSByung-Kwen Song
Byung-Kwen Song
As a power system develops rapidly into a smarter and more flexible state, so must the communication technologies that support it. Machine-to-machine (M2M) communication in a Smart Grid environment has been discussed by the European Telecommunications Standards Institute (ETSI). A power system is not easily replaceable, due to system replacement costs. THE M2M gateway is required in other to improve interoperability in the M2M environment. The Distributed Network Protocol 3.0 (DNP3.0) is the most important standard in SCADA systems for power. It has been used for device data collection/control in Substation Systems and Distribution Automation Systems. If the DNP3.0 data model is combined with a set of contemporary web protocols, it can result in a significant shift. We selected the Constrained Application Protocol (CoAP) based on RESTful as the M2M protocol. It is a specialized web transfer protocol for use with constrained nodes and constrained networks. We used the OPNET Modeler 17.1 to compare the performance of Simple Object Access Protocol (SOAP) to that of CoAP. In this paper, we propose a CoAP-based M2M Gateway for a Distribution Automation system using DNP3.0 in a Smart Grid Environment.

18 April 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SRSeongShick Ryu
SeongShick Ryu
YNYunju Nam
Yunju Nam
NKNamkyoung Kim
Namkyoung Kim
ISInjae Shin
Injae Shin
EJEunhye Jeon
Eunhye Jeon
TSTaebo Sim
Taebo Sim